Vaccines to prevent viral hepatitis

New England Journal of Medicine

Volumn 336, Issue 3, 1997, Pages 196-204

  Lemon, Stanley M ^a,c   Thomas, David L ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS VACCINE;

ACTIVE IMMUNIZATION; ANAPHYLAXIS; ANTIBODY RESPONSE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; GUILLAIN BARRE SYNDROME; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION PAIN; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINE PRODUCTION;

HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS, VIRAL, HUMAN; HUMANS; VIRAL HEPATITIS VACCINES;

EID: 0031021442     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199701163360307     Document Type: Review

References (117)

1. Lemon SM, Shapiro CN. The value of immunization against hepatitis A. Infect Agents Dis 1994;3:38-49.
2. Krawczynski K. Hepatitis E. Hepatology 1993;17:932-41.
3. Lau JY, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993;342:1335-40.
4. Rizzetto M, Ponzetto A, Forzani I. Epidemiology of hepatitis delta virus: overview. Prog Clin Biol Res 1991;364:1-20.
5. Houghton M, Weiner A, Han J, Kuo G, Choo Q-L. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991;14:381-8.
6. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105:94-8.
7. Szmuness W, Much I, Prince AM, et al. On the role of sexual behavior in the spread of hepatitis B infection. Ann Intern Med 1975;83:489-95.
8. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies. JAMA 1990;263:1218-22.
9. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989;1:889-93.
10. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990;264:2231-5.
11. Thomas DL, Cannon RO, Shapiro CN, Hook EW III, Alter MJ, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994;169:990-5.
12. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994;330:744-50.
13. Simons JN, Leary TP, Dawson GJ, et al. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995;1:564-9.
14. Linnen J, Wages J Jr, Zhang-Keck Z-Y, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271:505-8.
15. Hepatitis surveillance. Report no. 56. Atlanta: Centers for Disease Control and Prevention, 1995.
16. Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:14-20.
17. Hurwitz ES, Holman RC, Neal JJ, Strine TW, Margolis HS. Chronic liver disease deaths associated with viral hepatitis in the United States, 1979-1988. In: Late breaker abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 10-14, 1992. Washington, D.C.: American Society for Microbiology, 1992. abstract.
18. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327:1899-905.
19. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984;307:178-80.
20. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171:Suppl 1:S44-S49.
21. Armstrong ME, Giesa PA, Davide JP, et al. Development of the formalin-inactivated hepatitis A vaccine, VAQTA, from the live attenuated virus strain CR326F. J Hepatol 1993;18:Suppl 2:S20-S26.
22. Lemon SM. Hepatitis A virus: current concepts of the molecular virology, immunobiology, and approaches to vaccine development. Rev Med Virol 1992;2:73-87.
23. Ohnuma H, Machida A, Okamoto H, et al. Allelic subtypic determinants of hepatitis B surface antigen (i and t) that are distinct from d/y or w/r. J Virol 1993;67:927-32.
24. Murphy BL, Maynard JE, Le Bouvier GL. Viral subtypes and cross-protection in hepatitis B virus infections of chimpanzees. Intervirology 1974;3:378-81.
25. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982;307:1481-6.
26. Waters JA, Kennedy M, Voet P, et al. Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992;90:2543-7.
27. Seeff LB, Beebe GW, Hoofnagle JH, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987;316:965-70.
28. Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995;181:1047-58.
29. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Microbiol 1995;13:29-60.
30. McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
31. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-40.
32. Beasley RP, Hwang L-Y, Lin C-C, Chien C-S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129-33.
33. 1996 Drug topics red book: pharmacy's fundamental reference. Montvale, N.J.: Medical Economics, 1996.
34. Recombivax HB. West Point, Pa.: Merck, 1995 (package insert).
35. Engerix-B. Philadelphia: SmithKline Beecham Pharmaceuticals, 1995 (package insert).
36. Clements ML, Miskovsky E, Davidson M, et al. Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or PreS2 + S antigens. J Infect Dis 1994;170:510-6.
37. Moulia-Pelat J-P, Spiegel A, Martin PMV, et al. A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 years. Vaccine 1994;12:499-502.
38. Schödel F, Kelly SM, Peterson DL, Milich DR, Curtiss R III. Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination. Infect Immun 1994;62:1669-76.
39. Davis HL, Michel M-L, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet 1993;2:1847-51.
40. The hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 1991;40(RR-13):1-19.
41. Hadler SC, Margolis HS. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. Boston: Blackwell Scientific, 1992:282-308.
42. Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella: summary of a report from the Institute of Medicine. JAMA 1994;271:1602-5.
43. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993;270: 2935-9.
44. Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988;109:101-5.
45. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985;254:3187-9.
46. Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989;7:425-30.
47. Winter AP, Follett EAC, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994;12:771-2.
48. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989;160:766-9.
49. Hadler SC, de Monzon MA, Lugo DR, Perez M. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine 1989;7:106-10.
50. Goldfarb J, Baley J, Medendorp SV, et al. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. Pediatr Infect Dis J 1994;13:18-22.
51. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209-14.
52. Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine: a cost reduction strategy. JAMA 1985;254:3203-6.
53. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303:833-41.
54. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981;1:377-85.
55. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control Multi-Center Efficacy Trial among homosexual men. Ann Intern Med 1982;97:362-6.
56. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987;257:2612-6.
57. Whittle HC, Maine N, Pilkington J, et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995;345:1089-92.
58. Marion SA, Tomm Pastore M, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994;140:734-46.
59. Xu ZY, Duan SC, Margolis HS, et al. Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. J Infect Dis 1995;171:54-60.
60. West DJ, Watson B, Lichtman J, Hesley TM, Hedberg K. Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. Pediatr Infect Dis J 1994;13:745-7.
61. Dienstag JL, Stevens CE, Bhan AK, Szmuness W. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen. Ann Intern Med 1982;96:575-9.
62. Pol S, Driss F, Michel M-L, Nalpas B, Berthelot P, Brechot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994;344:342.
63. Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep 1982;31:317-28.
64. National, state, and urban area vaccination coverage levels among children ages 19-35 months - United States, April 1994-March 1995. MMWR Morb Mortal Wkly Rep 1996;45:145-50.
65. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13:Suppl 1:S47-S49.
66. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990;336:325-9.
67. Fortuin M, Karthigesu V, Allison L, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 1994;169:1374-6.
68. Andre FE, Hepburn A, D'Hondt E. Inactivated candidate vaccines for hepatitis A. Prog Med Virol 1990;37:72-95.
69. Lewis JA, Armstrong ME, Larson VM, et al. Use of a live attenuated hepatitis A vaccine to prepare a highly purified, formalin-inactivated hepatitis A vaccine. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:94-7.
70. Lemon SM, Robertson BH. Current perspectives in the virology and molecular biology of hepatitis A virus. Semin Virol 1993;4:285-95.
71. Lemon SM, Binn LN. Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 1983;148:1033-9.
72. Ping L-H, Lemon SM. Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies. J Virol 1992;66:2208-16.
73. Stapleton JT, Raina V, Winokur PL, et al. Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles. J Virol 1993;67:1080-5.
74. Lemon SM, Jansen RW, Brown EA. Genetic, antigenic and biologic difterences between strains of hepatitis A virus. Vaccine 1992;10:Suppl 1: S40-S44.
75. Provost PJ, Hilleman MR. Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 1979;160:213-21.
76. Binn LN, Lemon SM, Marchwicki RH, Redfield RR, Gates NL, Bancroft WH. Primary isolation and serial passage of hepatitis A virus strains in primate cell cultures. J Clin Microbiol 1984;20:28-33.
77. Midthun K, Ellerbeck E, Gershman K, et al. Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis 1991;163:735-9.
78. Sjogren MH, Purcell RH, McKee K, et al. Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate. Vaccine 1992;10:Suppl 1:S135-S137.
79. Havrix. Philadelphia: SmithKline Beecham Pharmaceuticals, 1995 (package insert).
80. Vaqta. West Point, Pa.: Merck, 1996 (package insert).
81. Iino S, Fujiyama S, Horiuchi K, et al. Clinical trial of a lyophilized inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine 1992;10:323-8.
82. Garin D, Vidor E, Wallon M, et al. Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults. Vaccine 1995; 13:220-4.
83. Loutan L, Bovier P, Althaus B, Glück R. Inactivated virosome hepatitis A vaccine. Lancet 1994;343:322-4.
84. Ambrosch F, Wiedermann G, André FE, et al. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol 1994;44:452-6.
85. Ellerbeck EF, Lewis JA, Nalin D, et al. Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A. Vaccine 1992;10:668-72.
86. Newcomer W, Rivin B, Reid R, et al. Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children. Pediatr Infect Dis J 1994;13:640-2.
87. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328-34.
88. Hoke CH Jr, Egan JE, Sjogren MH, et al. Administration of hepatitis A vaccine to a military population by needle and jet injector and with hepatitis B vaccine. J Infect Dis 1995;171:Suppl 1:S53-S60.
89. Delem AD. Comparison of modified HAVAB and ELISA for determination of vaccine-induced anti-HAV response. Biologicals 1992;20:289-91.
90. Binn LN, MacArthy PO, Marchwicki RH, et al. Laboratory tests and reference reagents employed in studies of inactivated hepatitis A vaccine. Vaccine 1992;10:Suppl 1:S102-S105.
91. Stapleton JT, Jansen RW, Lemon SM. Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. Gastroenterology 1985;89:637-42.
92. Green MS, Cohen D, Lerman Y, et al. Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin. J Infect Dis 1993;168:740-3.
93. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327:453-7.
94. Lemon SM. Inactivated hepatitis A vaccines. JAMA 1994;271:1363-4.
95. Purcell RH, D'Hondt E, Bradbury R, Emerson SU, Govindarajan S, Binn L. Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine 1992;10:Suppl 1:S148-S151.
96. Asher LVS, Binn LN, Mensing TL, Marchwicki RH, Vassell RA, Young GD. Pathogenesis of hepatitis A in orally inoculated owl monkeys (Aotus trivirgatus). J Med Virol 1995;47:260-8.
97. Lemon SM. Type A viral hepatitis: new developments in an old disease. N Engl J Med 1985;313:1059-67.
98. Poovorawan Y, Tieamboonlers A, Chumdermpadetsuk S, Glück R, Cryz SJ Jr. Control of a hepatitis A outbreak by active immunization of high-risk susceptible subjects. J Infect Dis 1994;169:228-9.
99. Ogra PL, Fishaut M, Gallagher MR. Viral vaccination via the mucosal routes. Rev Infect Dis 1980;2:352-69.
100. Stapleton JT, Lange DK, LeDuc JW, Binn LN, Jansen RW, Lemon SM. The role of secretory immunity in hepatitis A virus infection. J Infect Dis 1991;163:7-11.
101. Protection against viral hepatitis: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1990;39(RR-2):1-26.
102. Prevention of hepatitis A through active or passive immunization. MMWR Morb Mortal Wkly Rep (in press).
103. Hadler SC, McFarland L. Hepatitis in day care centers: epidemiology and prevention. Rev Infect Dis 1986;8:548-57.
104. Xu Z-Y, Fu T-Y, Margolis HS, et al. Impact and control of viral hepatitis in China. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:700-5.
105. Mao JS, Dong DX, Zhang HY, et al. Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans. J Infect Dis 1989;159: 621-4.
106. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
107. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994;91:7792-6.
108. Koziel MJ, Dudley D, Wong JT, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992;149:3339-44. [Erratum, J Immunol 1993;150:2563.]
109. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994;68:1494-500.
110. Weiner A, Erickson AL, Kansopon J, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A 1995;92: 2755-9.
111. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-40.
112. Choo Q-L, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994; 91:1294-8.
113. De Cock KM, Govindarajan S, Chin KP, Redeker AG. Delta hepatitis in the Los Angeles area: a report of 126 cases. Ann Intern Med 1986;105: 108-14.
114. Taylor JM. The structure and replication of hepatitis delta virus. Annu Rev Microbiol 1992;46:253-76.
115. Karayiannis P, Saldanha J, Jackson AM, et al. Partial control of hepatitis delta virus superinfection by immunisation of woodchucks (Marmota monax) with hepatitis delta antigen expressed by a recombinant vaccinia or baculovirus. J Med Virol 1993;41:210-4.
116. Burans JP, Sharp T, Wallace M, et al. Threat of hepatitis E virus infection in Somalia during Operation Restore Hope. Clin Infect Dis 1994;18:100-2.
117. Tsarev SA, Tsareva TS, Emerson SU, et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Natl Acad Sci U S A 1994;91:10198-202.